Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 10 (7), 514-23

Envisioning the Future of Early Anticancer Drug Development

Affiliations
Review

Envisioning the Future of Early Anticancer Drug Development

Timothy A Yap et al. Nat Rev Cancer.

Abstract

The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

Similar articles

See all similar articles

Cited by 79 PubMed Central articles

See all "Cited by" articles

References

    1. Cancer Res. 2004 Oct 1;64(19):7099-109 - PubMed
    1. J Clin Oncol. 2005 Jun 20;23(18):4152-61 - PubMed
    1. Clin Cancer Res. 2008 Oct 1;14(19):6302-9 - PubMed
    1. Nature. 2009 Apr 9;458(7239):719-24 - PubMed
    1. J Clin Oncol. 2009 Nov 20;27(33):5650-9 - PubMed

Publication types

Substances

LinkOut - more resources

Feedback